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consent approved by the Cleveland Clinic Institutional Re-
view Board. History of HF was detected by (a) directly
asking patient by research personnel, (b) reviewing medical
records for conﬁrmation (all patients were seen by cardiol-
ogist at Cleveland Clinic before the left heart catheteriza-
tion), and (c) ICD codes and adjudication by research
personnel. This analysis included 1,579 subjects with HF
with the New York Heart Association functional class II to
IV without evidence of myocardial infarction (cardiac
troponin I <0.03 ng/ml) with hematologic data available for
analysis. Five-year survival was ascertained for all subjects
after enrollment through a combination of prospective pa-
tient contact, electronic medical record review, and
conﬁrmed by the Social Security Death Index.
Complete blood cell count was performed on blood
samples collected at the day of enrollment using ADVIA
120 hematology analyzer (Siemens, New York, New York).
Anemia was deﬁned as Hb <13 g/dl for men and <12 g/dl
for women.15 Indexes of anemia included Hb, hematocrit,
MCHC (ratio of Hb to hematocrit), and mean corpuscular
volume (MCV). The normal range of MCHC is 33 to
36 g/dl.16 Nonanemic patients were grouped into quartiles
based on MCHC levels.
Follow-up levels of Hb and MCHC levels were obtained
from reviewing the electronic medical records when these
tests were measured for clinical purposes. To study change
of MCHC levels over time, a ﬁxed cutoff of 180  90 days
was used, and level closest to day 180 was selected. Only
nonanemic patients on baseline and follow-up were
analyzed to assess effect of MCHC change over time on
patient’s outcome. To study the effect of MCHC change
over time on outcomes, patients were grouped using cutoff
of quartile 1 for MCHC; thus, 4 groups were identiﬁed:
persistent hypochromia, resolving hypochromia, new
hypochromia, and no hypochromia (Figure 1).
HF severity was assessed based on plasma B type
natriuretic peptide levels (BNPs; using Abbott Architect
ci8200; Abbott Laboratories, Abbott Park, Illinois) and
Duke Activity Score Index (DASI)9,17 on day of enrollment.
Left ventricular ejection fraction (LVEF) was collected for
all patients. High-sensitivity C-reactive protein (hsCRP),
ceruloplasmin, and serum arylesterase activity were all
measured at the time of enrollment in a randomly selected
sample of 790 patients. Ceruloplasmin and hsCRP were
measured by Abbott Architect ci8200 (Abbott
Laboratories).18,19 Serum arylesterase activity level was
determined using a modiﬁcation of a spectrophotometry-
based assay as previously described.20
The Student’s t test, Wilcoxon rank-sum test, or Kruskal-
Wallis test for continuous variable and the chi-square test
for categorical variables were used to examine the difference
between the groups. Kaplan-Meier analysis and Cox pro-
portional hazards regression were used for time-to-event
analysis to determine hazard ratio and 95% conﬁdence in-
tervals (CIs) for 5-year survival. Levels of MCHC were
adjusted for traditional cardiac risk factors in a multivariate
model, including age, gender, diabetes mellitus, systolic
blood pressure, hyperlipidemia, creatinine clearance,
smoking, coronary artery disease, LVEF, body mass index,
and medications (angiotensin-converting enzyme inhibitors/
angiotensin receptor blockers, b blockers, and aspirin).
Analyses were repeated after adjusting for Hb, MCV, and
DASI. All statistical analyses were performed using R
2.15.1(Vienna, Austria).
Results
Table 1 lists the baseline characteristics of 1,579 patients
with stable HF enrolled in this study. Mean Hb and MCHC
were 12.6  1.6 g/dl and 33.9  1.2 g/dl, respectively (all
normally distributed). About half of the patients (n ¼ 785
[49.7%]) were nonanemic. Among this nonanemic group,
the median MCHC was 34.3 g/dl (interquartile range of 33.6
to 35 g/dl). Patients with low levels of MCHC were more
likely to be women, have lower creatinine clearance, and
have less prevalence of smoking and coronary artery disease
(Table 1).
Anemic patients with HF showed increased risk of 5-year
mortality (hazard ratio 2.2, 95% CI 1.8 to 2.7, p <0.001).
Overall, patients with lower MCHC had increased mortality
risk (quartiles 1 vs 4, hazard ratio 2.5, 95% CI 2.0 to 3.3, p
<0.001). Among patients with normal Hb levels, patients
with decreased MCHC levels have increased mortality risk
in a graded pattern (Figure 2, Table 2). All results remained
signiﬁcant even after multivariate adjustments with tradi-
tional coronary risk factors and known prognostic car-
diorenal, hematologic variables, and DASI (Table 2).
Furthermore, patients with low MCHC levels at baseline
had signiﬁcantly increased HF severity assessed by BNP
levels (neurohormonal upregulation) and DASI (functional
capacity) but not with LVEF (Table 3).
A total of 552 (35%) subjects had follow-up Hb levels
that met our inclusion criteria. Mean time between baseline
and follow-up samples was 169  42 days. No signiﬁcant
differences were found between selected patients with
follow-up level and those without, in regard to HF severity
(LVEF, DASI, and BNP), adverse outcomes (5-year mor-
tality), and hematologic indexes (Hb, MCV, and MCHC),
suggesting this subgroup is a good representative of the total
study population (Supplemental Table 1). In this longitu-
dinal cohort, mean baseline Hb and MCHC were 12.6  1.6
and 33.9  1.2 g/dl, respectively. Mean follow-up Hb and
MCHC were 12.8  2.0 and 33.0  1.3 g/dl, respectively.
About half of the patients were nonanemic (n ¼ 271, 49.1%)
at baseline, and most were nonanemic on follow-up
(n ¼ 311, 56.3%). In the nonanemic group at baseline,
Figure 1. Change in MCHC levels in nonanemic patients over time.
patients with low MCHC did not have increased risk of
developing anemia (less than vs more than quartile 1, odds
ratio 1.8, 95% CI 0.96 to 3.2, p ¼ 0.067).
Effect of MCHC change over time on long-term survival
was studied in patients with normal Hb both at baseline and
at follow-up (n ¼ 206). Patients with low MCHC (“relative
hypochromia,” less than quartile 1) were compared with
those with high MCHC (“normochromia,” quartile 1 or
more). Most of the patients with low MCHC on baseline
have also low MCHC on follow-up “persistent hypo-
chromia,” whereas about half of the patients with high
MCHC at baseline continued to have high MCHC levels
“no hypochromia” (Figure 1). In comparison with patients
with no hypochromia, patients with persistent hypochromia
had signiﬁcant increased mortality risk (log rank <0.001,
Figure 3).
We also examined the relation between MCHC levels in
nonanemic patients with heart failure and markers of
inﬂammation and systemic oxidative stress (Table 3). Of
the 790 patients with available biomarkers levels, 398
patients were nonanemic. In nonanemic patients with HF
with low MCHC levels, we observed graded and signiﬁ-
cantly high-level hsCRP and ceruloplasmin, consistent
with heightened systemic inﬂammation. Serum levels of
arylesterase activity, a cardioprotective antioxidant activity
catalyzed by high-density lipoprotein-associated para-
oxonase-1,20 were signiﬁcantly lower in patients with low
MCHC an indication of heightened oxidative stress
(Table 3).
Discussion
The primary ﬁnding of our study is the association be-
tween the presence and persistence of relative hypochromia
(as deﬁned by low MCHC levels, a readily available
parameter in complete blood count analysis) and increased
risk of 5-year all-cause mortality. This was especially
notable in nonanemic patients with HF, a subgroup for
whom no clinical consensus yet exists regarding approach,
monitoring, and treatment. Furthermore, we observed sig-
niﬁcant impairment in functional activity in patients with
relative hypochromia and heightened inﬂammatory and
reduced antioxidative processes. Interestingly, low MCHC
Table 1
Baseline characteristics of total population and non anemic population based on MCHC levels
MCHC levels, g/dL Whole
cohort
Non Anemic population p value*
All
Non
anemic
Quartile1
<33.6
Quartile2
33.6 34.3
Quartile3
34.3 35
Quartile4
35
Number 1579 785 196 195 197 197
Age (years) 6611 6411 6511 6611 6411 6310 <0.001
Male sex 65% 65% 50% 57% 71% 82% <0.001
Body mass index (kg/m2) 307 317 329 318 317 306 <0.001
Systolic blood pressure (mmHg) 13122 13121 13423 13121 13121 12819 <0.001
Diabetes mellitus 39% 34% 38% 35% 29% 34% 0.311
Hyperlipdemia 83% 82% 81% 77% 83% 86% 0.182
Smoker 72% 73% 70% 74% 76% 72% 0.542
Creatinine clearance (mL/min) 834 9443 8745 9140 9843 9844 <0.001
Coronary artery disease 76% 70% 62% 70% 72% 77% 0.007
Myocardial infarction 58% 56% 50% 54% 56% 64% 0.058
Ejection fraction (%) 40 (25 e 55) 35 (25 55) 35 (20 55) 40 (30 55) 40 (30 55) 35 (25 50) 0.124
Brain natriuretic peptide (pg/mL) 310 (114 695) 204 (91 499) 398 (125 951) 266 (107 686) 173 (78 376) 140 (73 371) <0.001
Heart failure with preserved EF 37% 36% 35% 42% 38% 28% 0.048
Angiotensin converting enzyme
inhibitors/ angiotensin receptor blockers
68% 67% 66% 70% 61% 70% 0.226
Beta blockers 67% 66% 64% 63% 68% 68% 0.644
Aspirin 66% 66% 59% 66% 61% 76% 0.003
Hemoglobin (g/dL) 12.61.6 13.81.1 13.71.1 13.61.1 13.81 14.11.1 <0.001
MCHC (g/dL) 33.91.2 34.21.1 32.80.8 340.2 34.60.2 35.50.4 <0.001
MCV (ﬂ) 88.85.7 895 89.35.8 89.55.2 894.4 88.34.3 <0.001
MCHC mean corpuscular hemoglobin concentration; MCV mean corpuscular volume.
* p Value for the difference between MCHC quartiles in non anemic population.
Figure 2. Kaplan Meier plot for 5 year mortality stratiﬁed by baseline
MCHC levels in nonanemic patients with heart failure (n 785). Log rank
<0.001.
levels on baseline were not associated with increased risk of
developing anemia on follow-up. These ﬁndings highlight
the importance of recognizing and exploring the mecha-
nistic underpinnings of relative hypochromia in the setting
of chronic HF, above and beyond its contribution to
anemia.
Because MCHC is a direct assessment of the amount of
Hb incorporated into the erythrocytes, MCHC may serve as
a reliable and readily accessible indicator of erythrocyte iron
load,11 13,21 which has a high speciﬁcity (up to 96%) in
detecting iron deﬁciency.21 Iron is involved in multiple
physiological functions including oxygen transport (Hb),
oxygen storage (myoglobin), oxidative metabolism
(mitochondrial oxidative enzymes),7,22 and antioxidant ac-
tivity (ferritin, myoglobin) and also is involved in the syn-
thesis and degradation of lipids, carbohydrates, and
nucleotides.4,7,22 Traditionally, iron deﬁciency is only
considered important in the presence of anemia. Our current
ﬁndings argue that strict cut-points for assessing iron deﬁ-
ciency may miss out on identifying patients with relative
impairment in iron metabolism/utilization.
Iron deﬁciency has been studied in patients with heart
failure.4,22,23 Even in patients with normal Hb levels,
patients with iron deﬁciency showed decreased functional
capacity, LVEF, and adverse outcomes.4,22,23 Nonanemic
iron-deﬁcient patients had a twofold greater risk for death
than anemic iron-replete subjects.13 Furthermore, treatment
with iron compounds in nonanemic patients with low iron
load improved symptoms, functional capacity, and quality
of life but not survival.23 The last could be related to
short follow-up period in this study (only 24 weeks) and
low total event rates (only 2%). Gaber et al24 found that
correction of iron deﬁciency improves functional class and
walking distance in nonanemic iron-deﬁcient patients with
systolic HF. They also found signiﬁcant improvement of
diastolic and systolic functions using echocardiogram
after therapy despite lack of improvement of LVEF.24
Ongoing clinical trials are addressing the role of iron
supplementation in both anemic and nonanemic patients
with HF.
Patients with HF are more susceptible to development of
iron deﬁciency.25 This could be related to gradual depletion
of iron stores (absolute iron deﬁciency) because of low iron
intake, gastrointestinal blood loss, or iron malabsorption.25
Table 2
Association between MCHC levels and 5 year all cause mortality in non anemic HF patients
MCHC levels (g/dL) Quartile 1
<33.6
Quartile 2
33.6 34.3
Quartile 3
34.3 35
Quartile 4
35
5 year Death 58/196 29.6% 50/195 25.6% 37/197 18.8% 32/197 16.2%
Unadjusted Hazard ratio 2.1 (1.4 3.3)** 1.7 (1.1 2.7)* 1.2 (0.8 2.0) 1
Adjusted Hazard ratio (Model 1) 1.9 (1.2 3.1)* 1.7(1.0 2.7)* 1.3 (0.8 2.1) 1
Adjusted Hazard ratio (Model 2) 1.9 (1.1 3.0)* 1.7 (1.0 2.7)* 1.3 (0.8 2.1) 1
Adjusted Hazard ratio (Model 3) 1.7 (1.0 2.7)* 1.5 (0.9 2.4) 1.2 (0.7 1.9) 1
Model 1: Age, sex, diabetes, systolic blood pressure, smoking, hyperlipidemia, coronary artery disease, creatinine clearance, angiotensin converting enzyme
inhibitor/angiotensin receptor blocker, beta blockers, aspirin use, body mass index and LVEF; Model 2: Model 1 þ baseline hemoglobin and MCV; Model 3:
Model 2 þ DASI.
**p <0.01; *p <0.05.
Table 3
Distribution of cardiac severity, inﬂammatory and oxidative markers across MCHC quartiles in non anemic HF patients
MCHC levels All Quartile 1
<33.6
Quartile 2
33.6 34.3
Quartile 3
34.3e35
Quartile 4
35
P value
LVEF (%) 35 (25 55) 35 (20 55) 40 (30 55) 40 (30 55) 35 (25 50) 0.124
BNP (pg/ml) 204 (91 499) 398 (125 951) 266 (107 686) 173 (78 376) 140 (73 371) <0.001
DASI Score 30 (18 43) 24 (13 38) 26 (17 43) 35 (19 50) 38 (23 50) <0.001
hsCRP (mg/L) 3 (1 6) 4 (3 8) 3 (1 7) 3 (1.3 5.8) 2 (1 5) <0.001
Ceruloplasmin (mg/dL) 25 (21 29) 26.5 (23.6 30.9) 25.8 (21.8 30.7) 24.5 (20.5 28.3) 23 (20 26) <0.001
Arylesterase activity (mmoles/min/mL) 99 (81 117) 89 (75 113) 99 (86 114) 103 (83 120) 100 (81 117) 0.118
BNP B type natriuretic peptide; DASI Duke Activity Status Index score; hsCRP high sensitive C reactive protein; LVEF Left ventricular ejection
fraction.
Figure 3. Kaplan Meier plot for 5 year mortality by change in MCHC levels
at follow up in nonanemic patients with heart failure. Log rank <0.001.
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In HF, there is also an activation of proinﬂammatory cyto-
kines that block intestinal absorption of iron and divert iron
from the circulation into the reticuloendothelial system
(functional iron deﬁciency).2,26 In both scenarios, there is
decreased iron availability to targeted tissues and organs.4
Iron level in the blood or stores once it reaches a mini-
mum threshold is not as critical as how much iron that is
getting into functioning erythrocytes.27 Routine monitoring
of blood iron levels in all patients with heart failure is costly.
Using erythrocyte indexes (such as MCHC in our study) as a
surrogate marker of iron deﬁciency (both absolute and
functional),10,14,21,27 high-risk patients who might beneﬁt
from further iron studies/replacement therapy could be
identiﬁed.
Interestingly, the association among MCHC and HF
outcomes, severity, and oxidative and inﬂammatory
markers, was observed in a graded pattern. Thus, even
patients with low normal MCHC showed adverse outcomes
and increased oxidative stress. Both HF and iron deﬁciency
are associated with increased oxidative stress.28,29 Because
iron plays a central role in the formation and scavenging of
reactive oxygen species,29 low MCHC could be either a
contributing factor to increased oxidative in HF or a result
of increased oxidative state because of HF, which impairs
iron utilization. Taken together, the gradual decrease in
MCHC may be more reﬂective of HF severity and iron
metabolic disarrangement, more than arbitrary cutoffs of
MCHC.
Limitations include lack of traditional measure of iron
proﬁles (iron, transferrin, and ferritin) to establish clinical
evidence of iron deﬁciency; hence, we can only establish the
presence of relative hypochromia and not speciﬁcally iron
deﬁciency. We do not have complete data about cause of
death or other HF end points like hospitalization or 6-minute
walking test. Our study population is also a selected group
of high-risk patients who all had elective coronary angio-
gram for clinical purposes. However, with the relatively
large sample size, these ﬁndings corroborated the existing
literature in HF and anemia and iron deﬁciency, whereas
providing new evidence to support the prognostic role of
relative hypochromia as an independent predictor of in-
crease mortality in patients with heart failure with normal
Hb levels.
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